Explore the words cloud of the BIOCAPAN project. It provides you a very rough idea of what is the project "BIOCAPAN" about.
The following table provides information about the project.
Coordinator |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address contact info |
Coordinator Country | France [FR] |
Project website | http://www.biocapan.eu |
Total cost | 7˙998˙875 € |
EC max contribution | 7˙998˙875 € (100%) |
Programme |
1. H2020-EU.2.1.3.1. (Cross-cutting and enabling materials technologies) |
Code Call | H2020-NMP-2014-two-stage |
Funding Scheme | RIA |
Starting year | 2015 |
Duration (year-month-day) | from 2015-06-01 to 2019-09-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES | FR (PARIS 15) | coordinator | 1˙988˙570.00 |
2 | UNIVERSITE CATHOLIQUE DE LOUVAIN | BE (LOUVAIN LA NEUVE) | participant | 1˙364˙915.00 |
3 | CHARITE - UNIVERSITAETSMEDIZIN BERLIN | DE (BERLIN) | participant | 1˙194˙291.00 |
4 | NANOIMMUNOTECH SL | ES (VIGO PONTEVEDRA) | participant | 853˙225.00 |
5 | UNIVERSITE GRENOBLE ALPES | FR (GRENOBLE) | participant | 783˙878.00 |
6 | WAKE FOREST UNIVERSITY HEALTH SCIENCES | US (WINSTON SALEM NC) | participant | 764˙918.00 |
7 | ETABLISSEMENT FRANCAIS DU SANG | FR (LA PLAINE SAINT DENIS) | participant | 652˙940.00 |
8 | FMC BIOPOLYMER AS | NO (SANDVIKA) | participant | 236˙861.00 |
9 | EUROPEAN RESEARCH SERVICES GMBH | DE (MUENSTER) | participant | 159˙275.00 |
10 | UNIVERSITE GRENOBLE ALPES | FR (SAINT MARTIN D'HERES) | participant | 0.00 |
11 | UNIVERSITE JOSEPH FOURIER GRENOBLE 1 | FR (GRENOBLE) | participant | 0.00 |
The key therapeutic issue in diabetes mellitus type I and II is glycaemic control. Reductions of constant self-control, of insulin injections, and of long-term complications would have tremendous benefit for quality of life. The best therapy option is the transplantation of allogeneic islet cells, but the current state of the art limits the applicability of this approach. Implanting unprotected grafts requires lifelong administration of immunosuppressants, and protecting the cells against adverse immune reactions by current encapsulation strategies reduces their functionality and survival to an extend that makes frequent ‘refresher’ implantations necessary. Currently, a maximum of 2 years glycaemia regulation has been shown for the encapsulated approach.
In BIOCAPAN, bringing experts from different fields all together, we aim at developing an innovative treatment, based on the implantation of allogeneic islet cells that are embedded in a complex microcapsule. We will design a GMP-grade bioactive microcapsule that will maximize the long-term functionality and survival of pancreatic islets by prevention of pericapsular fibrotic overgrowth, in situ oxygenation, innovative extracellular matrix microenvironment reconstruction and immune-system modulation. We will establish a GMP-grade microfluidic microencapsulation platform to protect freshly harvested islets quickly in a standardized and reproducible way.
We aim for full preclinical validation and we will establish a complete protocol in accordance with the provisions of the Advanced Therapy Medicinal Products Regulation, in order to start clinical trials within one year after the end of the project. We aim for 5-years insulin injection free treatment, without immunosuppressants, which would tremendously benefit diabetes mellitus patients who require insulin (all Type I and about one in six Type II Diabetes Mellitus patients).
Demonstrator | Demonstrators, pilots, prototypes | 2020-04-01 18:38:32 |
Website and flyer | Websites, patent fillings, videos etc. | 2020-04-01 18:38:32 |
Take a look to the deliverables list in detail: detailed list of BIOCAPAN deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2019 |
Camille Laporte, Emily Tubbs, Justine Cristante, Anne-Sophie Gauchez, Sandra Pesenti, Frédéric Lamarche, Cécile Cottet-Rousselle, Catherine Garrel, Anaick Moisan, Jean-Marc Moulis, Eric Fontaine, Pierre-Yves Benhamou, Sandrine Lablanche Human mesenchymal stem cells improve rat islet functionality under cytokine stress with combined upregulation of heme oxygenase-1 and ferritin published pages: , ISSN: 1757-6512, DOI: 10.1186/s13287-019-1190-4 |
Stem Cell Research & Therapy 10/1 | 2020-04-01 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOCAPAN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BIOCAPAN" are provided by the European Opendata Portal: CORDIS opendata.
Tailored Elastin-like Recombinamers as Advanced Systems for Cell Therapies in Diabetes Mellitus: a Synthetic Biology Approach towards a Bioeffective and Immunoisolated Biosimilar Islet/Cell Niche
Read MoreALL-SCALE PREDICTIVE DESIGN OF HEAT MANAGEMENT MATERIAL STRUCTURES WITH APPLICATIONS IN POWER ELECTRONICS
Read More